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ABSTRACT
Cancer associated fibroblasts (CAFs) are key determinants of cancer progression. 
In prostate carcinoma (PCa), CAFs induce epithelial-mesenchymal transition (EMT) 
and metabolic reprogramming of PCa cells towards oxidative phosphorylation 
(OXPHOS), promoting tumor growth and metastatic dissemination. We herein 
establish a novel role for pyruvate kinase M2 (PKM2), an established effector of 
Warburg-like glycolytic behavior, in OXPHOS metabolism induced by CAFs. Indeed, 
CAFs promote PKM2 post-translational modifications, such as cysteine oxidation and 
Src-dependent tyrosine phosphorylation, allowing nuclear migration of PKM2 and the 
formation of a trimeric complex with hypoxia inducible factor-1α (HIF-1α) and the 
transcriptional repressor Differentially Expressed in Chondrocytes-1 (DEC1). DEC1 
recruitment is mandatory for downregulating miR205 expression, thereby fostering 
EMT execution and metabolic switch toward OXPHOS. Furthermore, the analysis of a 
cohort of PCa patients reveals a significant positive correlation between PKM2 nuclear 
localization and cancer aggressiveness, thereby validating our in vitro observations. 
Crucially, in vitro and in vivo pharmacological targeting of PKM2 nuclear translocation 
using DASA-58, as well as metformin, impairs metastatic dissemination of PCa cells in 
SCID mice. Our study indicates that impairing the metabolic tumor:stroma interplay 
by targeting the PKM2/OXPHOS axis, may be a valuable novel therapeutic approach 
in aggressive prostate carcinoma.
INTRODUCTION
The acquisition of malignant traits of a cell during 
tumorigenesis is strongly influenced by the surrounding 
microenvironment [1, 2]. Among stromal cells, cancer-
associated fibroblasts (CAFs) cross-talk with cancer cells 
to sustain tumor growth and enhance metastatic potential 
[3–5]. This bidirectional interplay has been reported in 
melanoma [6], breast [7] and prostate cancers (PCa) [8]. 
Particularly, we have shown that PCa cell-secreted IL-6 
plays a pivotal role in promoting stromal reactivity. Once 
activated, CAFs release matrix metalloproteases 2 and 9 
(MMP-2 and -9), eliciting a redox-dependent epithelial-to-
mesenchymal transition (EMT) in PCa cells. This results 
in the enhancement of invasive abilities, acquisition of 
stem-like traits finally leading to metastatic dissemination 
[8, 9]. Recently, microRNA 205 (miR205) has been 
demonstrated to be a negative regulator of EMT and its 
expression inversely correlated with tumor malignancy 
[10, 11]. Indeed, PCa cells decrease miR205 expression 
upon CAFs contact, allowing de-repression of ZEB1/2 
transcription factors and therefore promoting EMT [11].
Furthermore, CAFs and PCa cells establish a 
metabolic symbiotic cooperation: CAFs undergo Warburg 
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metabolism and therefore increase glucose consumption 
whilst enhancing lactate production, which is released in 
the extracellular compartment via the mono-carboxylate 
transporter 4 (MCT4). Conversely, PCa cells reactivate 
oxidative phosphorylation (OXPHOS) and exploit CAF-
derived lactate to fuel anabolic pathways and support cell 
growth even in glucose-free environment [12].
Pyruvate kinase (PK) controls the final and 
rate-limiting reaction of glycolysis. Although normal 
cells generally express the PKM1 isoform, tumor 
cells frequently switch to PKM2 expression [13, 14]. 
Particularly, PKM2 expression contributes to tumor cell 
metabolic alterations and is associated with Warburg 
metabolism [15, 16]. In contrast to PKM1, which 
is present in a constitutively tetrameric active form, 
PKM2 undergoes conformational conversion between 
a tetrameric/full active and a dimeric/less active state 
[17, 18]. A number of post-translational modifications 
have been reported to impair PKM2 enzymatic activity 
by promoting the tetramer to dimer conversion, including 
Tyr105 phosphorylation [19] and Cys358 oxidation [20]. 
Notably, the conversion to a less active state confers 
to PKM2 “non-metabolic” abilities. Indeed, PKM2 
translocates into the nucleus and acts as a transcriptional 
co-activator of β-catenin and hypoxia-inducible factor 1α 
(HIF-1α), cooperating to control cell proliferation and 
glucose catabolism, respectively [21, 22].
We herein demonstrate that upon CAFs 
exposure, nuclear PKM2 controls EMT and metabolic 
reprogramming of PCa cells, thereby connecting 
motility and OXPHOS behavior. Once oxidized 
and phosphorylated, PKM2 translocates into the 
nucleus, interacts with HIF-1α and recruits the basic 
helix-loop-helix protein Differentially Expressed in 
Chondrocytes-1 (DEC1). This trimeric complex drives 
miR205 transcriptional suppression leading to EMT 
accomplishment and metabolic conversion to OXPHOS 
of PCa cells.
RESULTS
PKM2 in PC3 cells is oxidized and 
phosphorylated upon CAFs conditioning
We have previously demonstrated that CAFs can 
induce cyclooxygenase 2-mediated oxidative stress in 
PC3 cells, leading to EMT execution [9]. Here, we show 
that 24 h administration of CAFs conditioned medium 
(CM) to PC3 cells leads to transient oxidation of PKM2, 
which reverts to the reduced state after 48 h of CAFs 
conditioning (Figure 1A). A similar result was obtained 
by treating PC3 cells with human prostate fibroblasts 
(HPFs) activated in vitro by exposure to CM derived from 
PCa cells (PCaAF) (Figure 1A). In addition to reversible 
oxidation, PKM2 undergoes a tyrosine phosphorylation in 
response to CAFs exposure that is observed both at 24 and 
48 h (Figure 1A). The tyrosine kinase Src is a known redox 
sensor already reported to play a role in PCa metastatic 
behavior [23, 24]. Therefore, we analyzed Src redox state 
upon CAFs contact: CAFs-induced oxidative burst leads to 
Src oxidation (Figure 1B) that is paralleled by an increase 
in Src Y416 phosphorylation (Figure 1C), an indication 
of Src kinase activation. Moreover, Src associates 
with PKM2 following CAFs conditioning, suggesting 
a direct Src involvement in PKM2 phosphorylation 
(Figure 1D). In keeping with previous reports, oxidation 
and phosphorylation of PKM2 induce the destabilization 
of the tetrameric complex and the conversion towards a 
dimeric less metabolic active state (Figure 1E).
CAFs induce PKM2 nuclear localization and 
association with HIF-1α
It is established that PKM2 in its dimeric state can 
translocate into the nucleus and exert a non-metabolic 
function [18]. Accordingly, CAF-induced PKM2 oxidation 
and phosphorylation allows its translocation into the 
nucleus, where PKM2 associates with the transcriptional 
factor HIF-1α (Figure 1F). To confirm the role of Src 
kinase in ensuring PKM2 phosphorylation/inactivation 
we transfected PC3 cells with the redox insensitive Src 
mutants (Src C245A and C487A) [23]. Ectopic expression 
of Src C245A and Src C487A strongly impairs PKM2 
tyrosine phosphorylation and association with HIF-
1α (Figure 1G), although the nuclear localization of 
the enzyme is unaffected (Supplementary Figure S1). 
Conversely, HPF-CM did not have any major effects 
on PKM2 function and localization (Figure 1A–1G), 
suggesting an exclusive role for CAFs.
DASA-58-mediated PKM2 reactivation prevents 
its nuclear localization and association with HIF-
1α, thereby blocking EMT
To unravel the role of the CAF-induced PKM2 
inactivation and nuclear localization in PC3 cells, we 
analyzed the effect of synthetic PKM2 reactivation 
induced by DASA-58, which enhances PKM2 activity by 
inducing the tetramer formation [17]. Administration of 
DASA-58 during CAFs conditioning of PC3 cells is able 
to restore PK activity (Figure 2A), thereby abrogating the 
nuclear translocation of PKM2, as well as its association 
with HIF-1α (Figure 2B). Moreover, the impairment 
of PKM2/HIF-1α association significantly affects the 
expression of miR205, a critical miRNA driving CAF-
mediated EMT in PCa cells [11] (Figure 2C). Indeed, 
miR205 downregulation induced by CAFs exposure is 
completely counteracted by DASA-58 treatment (Figure 
2C). Interfering with PKM2 enzymatic activity by DASA-
58 treatment impairs stromal-induced EMT program as 
indicated by both the analysis of established EMT markers 
(Figure 2D) and PC3 cells invasiveness (Figure 2E).
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PKM2 reactivation restores glucose dependency 
of PC3 cells, still sustaining OXPHOS
We have previously shown a reciprocal metabolic 
reprogramming between CAFs and PCa cells. CAFs 
converted to Warburg metabolism, release lactate 
which is rapidly uptake by PCa cells to fuel metabolic 
pathways and OXPHOS, sustaining their energetic 
needs and growth [12]. Here, we investigated the effect 
of PKM2 reactivation on this metabolic circuitry. 
DASA-58 administration severely impairs CAF-induced 
upregulation of MCT1 and prevents CAF-induced 
downregulation of the glucose transporter Glut-1 (Figure 
3A). Accordingly, DASA-58 reactivation of PKM2 
restores PC3 cells glucose consumption (Figure 3B) 
while impairing their ability to import CAF-derived 
lactate (Figure 3C). Despite DASA-58 administration 
is able to convert PC3 cells from a lactate-dependent to 
a glucose-dependent metabolism, the OXPHOS ability 
of PC3 cells is unaffected. Indeed, DASA-58 treatment 
Figure 1: CAFs conditioning promotes PKM2 oxidation and tyrosine phosphorylation, leading to its nuclear 
localization and association with HIF-1α. PC3 cells were cultured in serum-free medium (ST) or with CM from HPFs, PCaAFs  
(in vitro activated HPFs by PC3-CM) or patient-derived CAFs for 24 h or 48 h. A. PC3 cell were lysed in presence of BIAM and PKM2 was 
immunoprecipitated (IP). Western blot (WB) with HRP-streptavidin and with anti P-Tyr antibody were performed to evaluate the reduced form 
of PKM2 and its tyrosine phosphorylation, respectively. Anti-PKM2 antibody was used for normalization. B. Src kinase IP from BIAM-labeled 
lysates were subject to anti HRP-streptavidin (to reveal the reduced form of Src) and to anti-Src for normalization. C. Total cell lysates were 
subject to WB using the anti Src-Tyr 416 or anti Src antibodies. D. PKM2/Src association was revealed by WB analysis on PKM2 IP using 
an anti-Src antibody. PKM2 immunoblot was used for normalization. E. The analysis of PK activity was performed on PC3 cells after 24 h 
or 48 h of treatment with CM from HPFs or CAFs. *p < 0.005 vs HPF. F. Nuclear and cytosolic fractions derived from HPFs CM or CAFs 
CM 48 h treated PC3 cells were subject to PKM2 IP. Anti-HIF-1α and anti-PKM2 immunoblots were used to evaluate a direct association of 
the two proteins and for normalization, respectively. Lamin and histone H3 immunoblot were used as a control for nuclear extraction. G. The 
redox insensitive Src mutants (C245A and C487A) and Src wt plasmids were transfected into PC3 cells and after 24 h cells were incubated for 
additional 48 h with HPFs CM or CAFs CM. Total cell lysates were subject to PKM2 IP and WB analysis performed using the listed antibodies.
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during CAFs conditioning promotes a significant increase 
of glucose respiration (Figure 3D). Conversely, DASA-
58 does not significantly impact on lactate extrusion of 
PC3 cells (Figure 3E). Therefore, DASA-58-induced 
PKM2 metabolic reactivation is sufficient to abolish 
the energetic symbiosis between PCa cells and CAFs, 
to restore glucose dependency in cancer cells, while 
maintaining their OXPHOS phenotype.
The ectopic expression of the redox insensitive 
Src C245A and Src C487A, which abrogates PKM2 
association with HIF-1α without interfering with its 
nuclear translocation, induces an effect comparable to 
DASA-58 administration. Indeed, expression of Src 
mutants reduces lactate uptake (Supplementary Figure 
S2A) and restores glucose consumption and respiration 
(Supplementary Figure S2B, S2C) without affecting 
lactate production and extrusion (Supplementary 
Figure S2D).
In order to clarify if the CAF-induced increase 
in lactate import, via MCT1 upregulation, could 
be responsible for EMT initiation in PC3 cells, we 
investigated the effect of the MCT1 inhibitor, AR-
C155858. The inhibition of the lactate importer 
significantly impairs EMT, suggesting a crucial role of 
lactate in the acquisition of PC3 pro-invasive features 
(Figure 3F). In keeping with the recent evidence linking 
mitochondrial ROS production to the enhancement of 
MCT1 expression and tumor cell migration [25, 26], 
we also show that interfering with mitochondrial ROS 
generation, using the mitochondria-targeted antioxidant 
MitoTEMPO, impairs EMT accomplishment and PC3 
invasiveness upon CAF-conditioning (Figure 3G–3H).
Figure 2: DASA-58 administration re-activates PKM2, impairs PKM2/HIF-1α nuclear association and abrogates 
EMT in PC3 cells. PC3 cells were cultured with CM from HPFs or CAFs for 48 h with or without 40 μM DASA-58. A. Measure of PK 
enzymatic activity. *p < 0.005 vs control CAF B. PKM2 IP from both nuclear and cytosolic fractions were subjected to WB for anti-HIF-
1α to evaluate PKM2/HIF-1α association. Anti PKM2 was used for normalization and anti-lamin as a control for nuclear extraction. Total 
amounts of HIF-1α on cell lysates were quantified by WB. C. miR-205 expression levels were quantified by qRT-PCR. Data are reported 
as log
10
-transformed relative quantity with respect to HPF-CM-PC3 treated cells. SNORD61 was used as comparator. *p < 0.001 vs control 
CAF D. EMT markers were monitored by WB with anti E-cadherin and anti vimentin antibodies. Actin was used for normalization. E. 
Invasion assay using Boyden chamber. Left, representative pictures are shown; right, bar graphs show the mean+SEM of the number of 
invading cells. For quantification six randomly chosen fields were counted. *p < 0.001 vs control CAF.
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CAFs induce the recruitment of the 
transcriptional repressor DEC1 to PKM2/HIF-
1α complex
To clarify the molecular mechanism that control 
miR205 expression, we evaluated whether other 
transcriptional regulators could be recruited at the PKM2/
HIF-1α complex. We focused our interest on DEC1 
(BHLHE40/STRA13/SHARP-2), a transcriptional repre-
ssor under the control of HIF-1α, already demonstrated 
to be involved in cancer aggressiveness and motility 
[27, 28]. Interestingly, in silico analysis of the miR205 
promoter region by Genomatix (www.genomatixsuite.
de), revealed one putative DEC1 binding site on the 3 
kb proximal promoter of the MIR205HG sense strand at 
-2975 bp -2961 bp (Figure 4A). In addition, we confirmed 
that CAFs conditioning induces DEC1 expression in PC3 
cells and that this regulation is not affected by DASA-58 
administration (Figure 4B). Silencing of HIF-1α before 
CAFs CM administration completely abrogates DEC1 
upregulation, confirming that HIF-1α is responsible for 
DEC1 induction upon CAFs CM exposure (Figure 4C). 
To assess whether DEC1 could be involved in prostate 
tumor:stroma interplay, we investigated the ability of DEC1 
to cooperate with PKM2 to drive the motogen pathway 
in PC3 cells. We found that PKM2 associates with both 
HIF-1α and DEC1 and that DASA-58 administration 
(i.e. impairment of PKM2/HIF-1α complex) interferes 
with DEC1 recruitment (Figure 4D left and right panels). 
Notably, DEC1 silencing does not affect the PKM2/HIF-1α 
complex formation (Figure 4E). In keeping with its role of 
transcriptional repressor, de novo expression of DEC1 and 
the formation of the trimeric complex DEC1/PKM2/HIF-
1α is mandatory for allowing miR205 downregulation after 
CAFs conditioning (Figure 4F) and for EMT induction 
(Figure 4G). The transcriptional repressive function of 
DEC1 is probably responsible also for the CAF-mediated 
reduction in glucose consumption via downregulation of 
Figure 3: PKM2 reactivation induced by DASA-58 restores glucose respiration, impairing CAFs driven lactate 
consumption. PC3 cells were cultured with CM from HPFs or CAFs for 48 h with or without 40 μM DASA-58 and subjected to different 
assays. A. The levels of the transporters MCT1 and Glut-1 were evaluated by immunoblotting. Actin immunoblot used for normalization is 
the same of Figure 2D, because it derives from the same experiment. B–C. Evaluation of [14C]-glucose (B) and [14C]-lactate uptake (C) were 
performed and normalized on protein content. D. Respiration of [14C]-glucose was evaluated as [14C]-CO2 release and normalized on protein 
content. E. PCa cells were cultured with CM from HPFs or CAFs for 48 h. Then media were changed with a serum-free one for additional 
16 h with or without 40 μM DASA-58. The amount of lactate released by PC3 cells was quantified and normalized on cell protein content. 
F–G. PC3 cells were cultured with CM from HPFs or CAFs for 48 h with or without 1 μM AR-C155858 (F) and 50 mM MitoTEMPO (G). 
EMT markers were analyzed by WB with anti E-cadherin and anti vimentin antibodies. Actin was used for normalization. H. PC3 cells 
were treated as in G and an invasion assay using Boyden chamber was then performed. Bar graphs show the mean+SEM of the number of 
invading cells. For quantification six randomly chosen fields were counted. *p < 0.005 vs control CAF.
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the transporter Glut-1. Indeed, in silico analysis of Glut-
1 promoter region unravels 4 putative DEC1 binding 
sites (Supplementary Figure S3A). In agreement, DEC1 
silencing impairs Glut-1 downregulation in CAF-
conditioned PC3 cells, thereby reactivating glucose import 
(Supplementary Figure S3B–S3C).
To further support the transcriptional repressive role 
of DEC1 in our model, we investigated the effect of the 
redox insensitive Src mutants (Src C245A and Src C487A) 
on DEC1/PKM2 association and the consequential 
modulation of miR205 expression. Since the redox 
insensitive Src mutants impair PKM2 phosphorylation and 
association with HIF-1α, the recruitment of DEC1 is also 
impaired (Supplementary Figure S4A). The absence of the 
PKM2/HIF-1α/DEC1 complex does not allow PC3 cancer 
cells to downregulate miR205 expression once treated 
with CAFs CM (Supplementary Figure S4B).
DEC1 association with the PKM2/HIF-1α complex 
was also confirmed in DU145 cells, another metastatic 
prostate carcinoma cell line (Supplementary Figure S5A). 
Figure 4: DEC1 is recruited by the PKM2/HIF-1α complex upon CAFs exposure, granting for miR205 transcriptional 
repression and EMT execution. A. Schematic representation of putative DEC1 binding site within the miR205 promoter region 
identified using Genomatix Suite. The putative sequence is indicated and the core sequence (four most conserved positions within the 
matrix) is highlighted in capital letter. B. PC3 cells were cultured with CM from HPFs or CAFs for 48 h with or without 40 μM DASA-58. 
DEC1 expression level was evaluated by WB with anti DEC1 antibody (DEC1 (S-8), sc-101023, Santa Cruz Biotechnology). An actin 
WB was used for normalization. C. HIF-1α was silenced in PC3 cells and after 24 h cells were incubated for additional 48 h with HPFs 
CM or CAFs CM (two different siRNA from Santa Cruz Biotechnology and Origene were used, with similar results). DEC1 and HIF-1α 
levels were evaluated by WB. Actin immunoblot was used for normalization. D. PC3 cells were treated as in B. (Left panel) PKM2 was 
immunoprecipitated and anti-HIF-1α and anti-DEC1 WB were performed to evaluate a direct association with PKM2. PKM2 immunoblot 
was used for normalization. (Right panel) DEC1 was immunoprecipitated and anti-HIF-1α and anti-PKM2 immunoblots were performed 
to assess the binding with DEC1. DEC1 immunoblot was used for normalization. E. DEC1 was silenced in PC3 cells and after 24 h cells 
were incubated for additional 48 h with HPFs CM or CAFs CM (two different siRNA from Santa Cruz Biotechnology and Origene were 
used, with similar results). PKM2/HIF-1α association was assessed by an anti-HIF-1α WB on PKM2 IP. PKM2 immunoblot was used 
for normalization. F. PC3 cells were treated as in E. qRT-PCR analysis of miR-205 expression is reported as log
10
-transformed relative 
expression with respect to HPF-CM-PC3 treated cells. *p < 0.001 vs silNeg CAF G. The levels of E-cadherin and vimentin were assessed 
by immunoblotting. The anti-actin WB was used for normalization, while the anti-DEC1 was performed as a control of silencing.
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As already observed in PC3 cells, DASA-58 administration 
abrogates the CAF-induced miR205 downregulation 
in DU145 cells (Supplementary Figure S5B), thereby 
interfering with the EMT execution and the pro-invasive 
input elicited by CAFs (Supplementary Figure S5C–S5E).
Metformin abolishes the PKM2-mediated EMT 
commitment induced by CAFs
Recent observations demonstrated a clear role of the 
anti-diabetic drug metformin in the reduction of primary 
tumor growth and metastatic colonization in several solid 
tumors [29]. In keeping with the established effect of 
metformin in inhibiting complex I of the mitochondrial 
electron transport chain [30], we observed that metformin 
reduces ROS levels in PC3 cells after CAFs conditioning 
(Figure 5A) and negatively affects both the oxidation 
and tyrosine phosphorylation of PKM2 (Figure 5B). 
The reduction of PKM2 phosphorylation is due to the 
metformin inhibitory effect on Src oxidation and kinase 
activation (Figure 5C, 5D). Metformin counteracts PKM2 
inactivation and therefore i) impairs the formation of 
the HIF-1α/DEC1/PKM2 trimeric complex (Figure 5E), 
ii) downregulates CAF-induced miR205 expression 
(Figure 5F), iii) inhibits CAF-induced EMT promotion 
(Figure 5G) and subsequent cells invasive ability (Figure 
5H). Comparable results were obtained in DU145 cells, 
confirming the ability of metformin to inhibit PKM2 
nuclear translocation and CAF-induced inhibition of 
miR205 expression, thereby impairing EMT execution 
(Supplementary Figure S6A–S6D).
Metformin abolishes the metabolic cooperation 
between CAFs and PC3 cells, converting cancer 
cells to a Warburg phenotype
Similar to what is observed for DASA-58, metformin 
administration regulates PKM2 nuclear function of PC3 
cells impacting on their metabolic pathways. Indeed, 
metformin treatment of CAFs-conditioned PC3 cells 
reduces MCT1 and increases Glut-1 expression levels, thus 
promoting PC3 cells to shift their metabolic dependency 
from lactate to glucose (Figure 6A–6C). Since metformin 
prevents OXPHOS by inhibiting mitochondrial respiratory 
chain complex I (Figure 6D), it forces PC3 cells to recover 
a “canonical” Warburg metabolism, increasing lactate 
extrusion and disrupting the metabolic symbiosis of PC3 
cells with stromal CAFs (Figure 6E).
Impairment of PKM2 nuclear association 
with HIF-1α and DEC1 abrogates metastatic 
colonization of PC3 cells
To confirm that CAF-induced PKM2 nuclear 
translocation is an essential requirement for PCa cells 
metastatic ability, we performed an experimental 
metastasis assay in SCID mice. PC3 cells where either 
silenced for DEC1 prior to CAFs conditioning or cultured 
in presence of CAFs-CM with or without DASA-58 
or metformin. SCID mice were i.v. injected with ex 
vivo treated cells and analysis of lung colonization was 
performed after 40 days from tail vein injection. Before 
injection, we checked the efficacy of drugs administration 
or DEC1 silencing in abrogating EMT (Figure 7A, right 
panel). CAFs conditioning of PC3 cells significantly 
increased (12-fold) lung metastatic nodules formation 
compared to HPF-treated PC3 (Figure 7A, left panel). 
Crucially, silencing of DEC1, as well as the treatment with 
DASA-58 or metformin, dramatically reduced (~6-fold) 
CAFs-induced lung metastases formation (Figure 7A, left 
panel).
Nuclear localization of PKM2 correlates with 
PCa malignancy in vivo
To further corroborate our in vitro and in vivo 
observations, we evaluated the intensity of PKM2 nuclear 
staining in prostate specimens derived from patients 
affected by PCa with different Gleason score (GS). Our 
analysis reveals a significant increase (P < 0.05) of PKM2 
nuclear localization in prostate carcinomas with higher 
(8–10) versus lower Gleason scores (6–7) (Figure 7B, 
7C). Together, our data demonstrate that CAFs promoted 
conversion of PCa cells towards a highly aggressive 
and metastatic phenotype is controlled by PKM2 
transition towards a less metabolically active state and 
the subsequent acquisition of a “non-metabolic” nuclear 
activity.
DISCUSSION
In the current manuscript, we highlight a novel 
function of PKM2 besides its established role in 
controlling the Warburg metabolic deregulation of 
cancer cells. Importantly, we demonstrate that PKM2 
is a master regulator of cancer cell motility induced by 
CAFs contact. In fact, CAFs promote PCa progression, 
enabling cancer cells to successfully colonize and 
generate metastatic disease to distant sites. Crucially, in 
response to CAFs contact, PKM2 undergoes metabolic 
inactivation through both oxidation and Src-mediated 
phosphorylation inducing PKM2 nuclear translocation. 
Once in the nucleus, PKM2 can associate with HIF-1α 
and the transcriptional repressor DEC1, thus culminating 
in miR205 regulation, EMT execution and enhancement 
of invasiveness (Figure 7D a,b). Finally, the in vitro data 
are fully supported by in vivo observations in both SCID 
mice and PCa patients-derived specimens (Figure 7C). 
Therefore, PKM2 plays an essential role in mediating 
both functions exerted by CAFs for cancer malignancy, 
i.e. enhance cell motility and control metabolic 
reprogramming of PCa cells.
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Figure 5: Metformin impairs PKM2 nuclear function and abrogates CAFs driven EMT in PC3 cells. PC3 cells were 
cultured with CM from HPFs or CAFs for 48 h with or without 5 mM metformin. A. H2O2 production was evaluated by H2DCF-DA 
spectrophotometric analysis, normalized on protein content. *p < 0.005 vs control CAF B. PKM2 IP from BIAM-labeled cell lysates 
were subjected to HRP-streptavidin, anti-P-Tyr and anti-PKM2 WB to evaluate the reduced form, the tyrosine phosphorylation and the 
total amount of PKM2, respectively. C. Src kinase was immunoprecipitated from BIAM-labeled lysates and the reduced form of Src was 
revealed by anti HRP-streptavidin WB. Src immunoblot was performed for normalization. D. Src activation was assessed by anti Src-Tyr 
416 immunoblot and normalized on Src total amount. E. PKM2 was immunoprecipitated from cell lysates and anti-HIF-1α and anti-DEC1 
WBs were performed to evaluate a direct association with PKM2. PKM2 immunoblot was used for normalization. F. qRT-PCR analysis of 
miR-205 expression is shown as log
10
-transformed relative expression compared to HPF-CM-PC3 treated cells. *p < 0.001 vs control CAF 
G. Expression of E-cadherin and vimentin was evaluated by WB. Actin immunoblot was used as loading control. H. Invasion assay using 
matrigel-coated Boyden chamber was performed using PC3 cells treated as indicated. Representative pictures are shown and quantification 
of six randomly chosen fields (n = 3) is reported in bar graphs as mean+SEM. *p < 0.001 vs control CAF.
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PKM2 expression correlates with cancer 
aggressiveness [13, 31–33] and represents the glycolysis 
bottleneck in cells undergoing Warburg metabolism (i.e. 
increased glucose uptake) [15, 19, 20]. Indeed, PKM2 
enzymatic activity can be functionally controlled by 
several post-translational modifications [34]: PKM2 
activity inhibition induces cancer cells to accumulate 
glycolytic intermediates that fuel aminoacid biosynthesis, 
pentose phosphate pathway and nucleotides anabolism, 
resulting in cancer growth promotion [15]. Although 
cancer cells may exploit different mechanisms to interfere 
with the glycolytic flux and fuel anabolism [35], PKM2 
is widely considered the leading regulator of the Warburg 
metabolism in cancer cells. Here, we involve PKM2 as a 
modulator of the lactate-addicted respiratory metabolism 
induced by CAFs-conditioning in highly stroma-infiltrated 
cancers, thereby expanding the functions controlled by 
this enzyme from glycolysis regulation to OXPHOS. In 
prostate or breast carcinomas, CAFs display a canonical 
Warburg behavior and secrete lactate [12, 36]. Conversely, 
cancer cells upload CAFs-produced lactate to sustain 
mitochondrial OXPHOS, anabolic pathways and cell 
growth [12]. Treatment with DASA-58, which interferes 
with CAFs-induced PKM2 functional (i.e. enzymatic) 
inhibition, induces loss of lactate addiction and restores 
glucose dependency in cancer cells, although maintaining 
a respiratory phenotype sustained by glucose respiration. 
It is therefore intriguing to suggest that DASA-58 may 
be used for tumor:stroma metabolic coupling disruption. 
Particularly, its activity in highly stromal-infiltrated 
cancers may be further enhanced by OXPHOS inhibitors 
co-administration.
CAFs-induced EMT is a redox dependent 
phenomenon, driven by Rac1b/cycloxygenase-2 
activation, which promotes the stabilization of the redox 
sensitive transcription factor HIF-1α, in turn sustaining a 
second wave of transcriptional activity due to ZEB1/2 and 
Snail-1 [9]. We now include both Src and PKM2, as direct 
targets of the CAF-induced pro-oxidant environment. 
Both these enzymes have already been reported as 
redox sensors [37]. PKM2 has been found oxidized in 
response to hypoxia and insulin stimulation, while Src 
Figure 6: Metformin increases glucose consumption in PC3 cells exposed to CAFs CM. PC3 cells were cultured with 
CM from HPFs or CAFs for 48 h with or without 5 mM metformin. A. The levels of MCT1 and Glut-1 were evaluated by WB and actin 
WB was used as loading control. B–C. Evaluations of [14C]-lactate (B) and [14C]-glucose uptake (C) were performed and normalized on 
total proteins. D. Respiration of [14C]-glucose was evaluated as [14C]-CO2 release and normalized on protein content. E. PCa cells were 
cultured with CM from HPFs or CAFs for 48 h. Then media were changed with a serum-free one for additional 16 h with or without 5 
mM metformin. The amount of lactate released by PC3 cells was quantified and normalized on protein content. *p < 0.005 vs control CAF.
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Figure 7: Nuclear translocation of PKM2 correlates with prostate carcinoma aggressiveness and with metastatic 
potential of PC3 cells. A. PC3 lung colonization in SCID bg/bg mice. PC3 cells were conditioned for 48 h with CM from HPFs or with 
CM from CAFs, with or without 40 μM DASA-58 or 5 mM metformin. Alternatively, PC3 cells were conditioned for 48 h with CAFs CM 
after 24 h of DEC1 silencing. Treated cells were then injected into the lateral tail vein of mice (n = 6 per group). Lung macrometastases 
were counted (*p < 0.001 vs control CAF). Immunoblot for E-cadherin and Vimentin and for DEC1 expression were performed as a control 
of EMT and DEC1 silencing, respectively. B. 29 primary prostate cancer tissues with different Gleason scores (Low GS corresponding to 
Gleason scores 6–7 and High GS corresponding to Gleason scores 8–10) were IHC stained with anti-PKM2 antibody to evaluate PKM2 
nuclear localization. The IHC staining was quantified based on the intensity and percentage of cells stained (see Materials and Methods for 
details). Bars represent mean +SEM (standard error of the mean) for Low and High GS *p < 0.05 vs Low GS C. Representative images for 
GS 3+4 (Low GS) and GS 5+5 (High GS) are shown. Scale bars = 200 μm. The marked areas are higher magnification of the highlighted 
areas (3X). D. Schematic representation of PKM2 central role in PCa cells upon HPFs or CAFs exposure. a. During HPFs conditioning, 
PC3 cells upload glucose by the microenvironment, mainly used to fuel glycolysis, with a little involvement of mitochondrial respiration. 
HPF-treated PC3 cells also maintain high levels of miR205, thus allowing the stabilization E-cadherin-mediated epithelial features. b. The 
pro-oxidant environment induced by CAFs drives the oxidation and the Src-mediated tyrosine phosphorylation of PKM2, promoting its 
nuclear association with HIF-1α/DEC1, downregulation of miR205 and EMT execution. In addition, PKM2 nuclear translocation favors 
the establishment of a metabolic circuitry between CAFs and PCa cells. The impairment of PKM2 nuclear function with DASA-58 or 
metformin administration abolishes EMT, motility and the metabolic dependence of PCa cells on CAF-derived lactate, restoring glucose-
dependency of cancer cells.
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is oxidized during hypoxia [38], upon cell adhesion 
to extracellular matrix (ECM) and in EGFR-mediated 
anoikis resistance [23, 24]. To our knowledge, this is the 
first report describing the concomitant redox regulation 
of both kinases, during CAFs-driven pro-inflammatory 
pathway that sustains metastases in PCa. Both regulations 
are functionally linked and collectively lead to PKM2 
conversion to a less active state. In addition, in our model 
the CAF-induced tyrosine phosphorylation of PKM2 
results from a direct association with Src. This is a novel 
finding, since Src has not been previously correlated to 
PKM2 phosphorylation.
Interestingly, our data also highlight a crucial 
role of PKM2 as a common regulator of both the motile 
and the metabolic features of cancer cells. The role of 
PKM2 in tumor cells is controverted. Besides its role 
in promoting cancer growth, Israelsen and colleagues 
reported that PKM2 genetic knock out increased breast 
tumorigenesis in a mouse model [39]. Herein, we 
show that PKM2 role in PCa progression is not merely 
associated to its expression, which is unaffected by 
CAFs conditioning, but also with the post-translational 
modifications induced by CAFs. These modifications 
are mandatory for PKM2 translocation into the nucleus, 
association with HIF-1α and DEC1 and induction of 
miR205-dependent EMT. In keeping with our data, 
Hamabe et al. recently reported a direct involvement 
of nuclear PKM2 in fostering TGFβ-mediated EMT in 
colon cancer cells. The authors propose a role for PKM2 
as a transcription cofactor of TGF-β-induced factor 
homeobox 2 in driving histone H3 deacetylation and 
inhibition of CDH1 expression [40].
Notably, our study indicates a positive correlation 
between nuclear PKM2 localization and prostate cancer 
aggressiveness in patient-derived tumor tissues. Nuclear 
migration of PKM2 has already been reported in several 
studies [21, 22], involving different mechanisms such as 
serine or tyrosine PKM2 phosphorylation and association 
of PKM2 with prolyl hydroxylases and JMJ demethylases 
[32, 41]. In this still evolving scenario, one possibility is 
that the controversial role of PKM2, that we proved to 
be importantly influenced by contact between cancer cells 
and CAFs, can be explained by different grades of stromal 
infiltration in different histotypes of cancers.
Our data indicate that both DASA-58 and 
metformin similarly affect EMT of prostate cancers 
and tumor dissemination in vivo. Both agents are able 
to interrupt the cross-talk between cancer cells and 
stromal CAFs, although only metformin is able to totally 
convert the lactate-dependent OXPHOS behavior into 
a Warburg-like metabolism. From a therapeutic point 
of view metformin is a very attractive molecule, non-
toxic, well tolerated and extremely cheap, and its use 
should be considered for clinical trials in association 
with lactate extrusion inhibition (e.g. MCTs inhibitors). 
Recent clinical trials suggest that metformin could be 
effective in prostate cancer patients [42, 43], and it is 
possible that the ability of this drug to interfere with the 
metabolic circuitry between cancer and stromal cells is 
the basis of its efficiency. In summary, our study suggests 
that targeting the PKM2-induced motogen pathways and 
metabolic coupling in PCa could be a potential therapeutic 
strategy.
MATERIALS AND METHODS
Materials
Unless specified, all reagents were obtained 
from Sigma and all the antibodies were from Santa 
Cruz Biotechnology, except for anti-HIF-1α (Becton 
Dickinson), anti-PKM2 and anti-Src-Tyr416 (Cell 
Signaling Technology) and anti phospho-Tyr (clone 
4G10) (Millipore). HRP-conjugated streptavidin 
was from Pierce. HIF-1-siRNA and DEC1-siRNA 
were from Santa Cruz Biotechnology. N-(biotinoyl)-
N-(iodoacetyl)ethylenediamine (BIAM) and 
2′-7′-dichlorofluoresceindiacetate (H2-DCF-DA) were 
from Molecular Probe. [U-14C] lactate and [U-14C] 
glucose were from Perkin Elmer. All the kits used to 
perform miRNA extraction and quantitative reverse 
transcriptase PCR were from Qiagen. Lipofectamine 
2000 was from Invitrogen. Metformin was obtained by 
Sigma. The chemical synthesis of the PKM2 activator 
DASA-58 was kindly performed by Dr. Richichi of the 
Department of Chemistry (University of Florence). The 
mitochondrial antioxidant MitoTEMPO was from Santa 
Cruz Biotechnology. The MCT1 inhibitor, AR-C155858, 
was from Tocris Bioscience.
Experimental models
Human PCa cells (PC3, DU145) were obtained 
and authenticated by PCR/short tandem repeat (STR) 
analysis from the European Collection of Cell Cultures 
and maintained at 37°C/5% CO2 in DMEM supplemented 
with 10% fetal bovine serum. Human prostate fibroblasts 
(HPFs and CAFs) were isolated from surgical explants 
after patient informed consent, in accord with the Ethics 
Committee of the Azienda Ospedaliera Universitaria 
Careggi, as described in [12].
Fibroblasts and PCa cells activation
HPFs and CAFs were grown to subconfluence and 
treated for 48 hours with serum-free medium to obtain 
HPFs CM and CAFs CM, respectively. Alternatively, 
HPFs were treated for 24 hours with CM from PC3 
(obtained culturing PCa cells in serum-free medium for 48 
hours) to obtain PCa-activated fibroblasts (PCaAF). PCa 
cells were treated with the CM collected from fibroblasts 
(HPFs, CAFs or PCaAFs) for 24 or 48 h.
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Cell transfection
Transient transfections with pSG5c-Src wt, 
C245A and C487A were performed with Lipofectamine 
(Invitrogen), following manufacturer’s instructions. The 
efficiency of transfection is 70% and has been evaluated 
by co-transfection with pEGFP-N1 (ratio pEGFP-N1/
pSG5c-Src). Silencing with siRNA was performed 
with Lipofectamine 2000 following manufacturer’s 
instructions.
Immunoprecipitation, immunoblot analysis and 
BIAM labeling
PCa cells (1 × 106) were lysed with RIPA buffer 
and 500 μg of total proteins were immunoprecipitated. 
Immunoblot was performed as reported in [8]. For 
detection of protein redox state, BIAM labeling was 
performed as previously described [24].
Preparation of nuclear extract
PCa cells were lysed in (10 mM HEPES pH 7.5, 
10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 0.5% 
Nonidet-40) for 15 min. After centrifugation (12.000g 
for 10 min) the supernatant was collected as cytoplasmic 
extract. The pelleted nuclei were resuspended for 30 min 
in ice in nuclear extraction buffer (20 mM HEPES pH 
7.5,400 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol). 
Nuclear extract was collected by centrifugation at 12.000 
g for 15 min.
Pyruvate kinase activity
PK activity was measured by a double reactions 
kinetic assay by lysing cells in 50 mM Tris-HCl pH 7.4, 
additioned with protease inhibitors and transferred to 
a TRAP/4 solution (100 mM triethanolamine, 10 mM 
EDTA, 16 mM MgSO4, pH 7.6) additioned of ADP 
100 mM, NADH 10 mM, PEP 40 mM, LDH (Sigma). 
The absorbance at 340 nm was monitored over 20 min 
(ε = 6.22 mM−1 cm−1).
Assay of intracellular reactive oxygen species 
(ROS)
To evaluate intracellular production of H2O2 cells 
were treated for 3 minute with 5 μg/ml H2DCF-DA. 
After PBS washing, cells were lysed in RIPA buffer and 
analyzed immediately by fluorimetric analysis at 510 nm. 
Data have been normalized to total protein content.
In vitro Boyden invasion assay
Invasion assay was performed with 5 × 104 PCa 
cells on 8-μm-pore Transwells (Corning) coated with 50 
μg/cm2 of reconstituted Matrigel for 16 h, as described 
in [9]. Chemotaxis was evaluated by counting the cells 
migrated to the lower surface of the filters (six randomly 
chosen fields).
miRNA analysis
Quantification of miR-205 expression levels was 
assessed by quantitative reverse transcriptase PCR (qRT-
PCR). Total RNA, including small RNAs, was purified 
using miRNeasy kit. The reverse transcription reaction 
of 1 μg of total RNA was carried on using miScript II 
RT kit and the quantification of miR205 expression level 
was assessed by Real Time PCR using miScript SYBR 
Green PCR kit and miScript Primer Assay-HsmiR-205. 
SNORD61 was used as normalizer (miScript Primer 
Assay-HsSNORD61, Qiagen). Amplifications were run 
on 7500 Fast Real-Time PCR System. Data were reported 
as relative quantity with respect to the calibrator sample 
using the 2−ΔΔCt method.
In silico binding site analysis
Three human MIR205 [NC_000001 (+) 209602165 
– 209605890] files generated by Gene2Promoter analysis 
(GXP_144577, GXP_144578, GXP_4402679) were used 
to determine sites of DEC1 binding using Mat Inspector 
(www.genomatixsuite.de). Putative binding sites for 
transcription factor were identified using a stringent search 
setting, with matrix similarity set at 1 and core similarity at 1 
(i.e. maximum stringency) to avoid the identification of false 
positives. The matrix represents the DNA binding profile 
for DEC1, with the matrix similarity being the quality of 
a match between the matrix and the input sequence. Core 
similarity represents the quality of a match between the core 
sequence of a matrix (the four most conserved positions 
within a matrix) and the input sequence.
Glucose and lactate uptake
PCa cells were treated with HPFs CM or CAFs CM 
for 48 hours, with or without drug administration. Glucose 
or lactate uptake was evaluated in a buffered solution (140 
mmol/L NaCl, 20 mmol/L Hepes/Na, 2.5 mmol/L MgSO4, 
1 mmol/L CaCl2, and 5 mmol/L KCl, pH7.4) containing 
0.5 μCi/mL [U-14C] glucose or [U-14C] lactate for 15 
minutes at 37°C. Cells were subsequently washed with 
cold PBS and lysed with 0.1 mol/L NaOH. Incorporated 
radioactive was assayed by liquid scintillation counting 
and normalized on protein content.
Detection of released CO2 by radioactive lactate
PCa cells were treated with CM for 72 hours and 
then 0.2 μCi/mL [U-14C] lactate was added for 15 minutes. 
Each dish had a taped piece of Whatman paper facing 
the inside of the dish wetted with 100 μL of phenyl-
ethylamine-methanol (1:1) to trap the CO2. Then 200 μL of 
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4M H2SO4 was added to cells. Finally, Whatman paper was 
removed and transferred to scintillation vials for counting.
Lactate assay
Lactate was measured in the cultured media with 
Lactate Assay kit (Source Bioscience Life Sciences) 
according to the manufacturer’s instruction.
Lung colonization assay
Male SCID-bg/bg mice (6–8 weeks old) were 
injected with PC3 previously conditioned ex vivo with 
CAFs, with or without drug treatment or DEC1 silencing 
for 48 h. Six mice per group were injected in the lateral 
tail veins with 1 × 106 PC3 cells, monitored every 3 days 
and sacrificed after 8 weeks. Lungs were inspected for 
micrometastases by histological analyses.
Immunohistochemistry (IHC)
IHC was performed on 29 paraffin-embedded and 
serially cut prostate cancer or lymph node tissues obtained 
from St. Joseph’s Hospital (Hamilton, Ontario, Canada), 
following patient consent and approval from the local 
Ethics Board. Slides were processed and analyzed as 
previously described [44].
Statistical analysis
Data are presented as means ± standard deviation 
from at least three independent experiments. Statistical 
analysis of the data was performed by unpaired t-test. p-
Values < p 0.05 were considered statistically significant.
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